2017 ESMO Meeting Highlights in Pancreatic Cancer


Multiple randomized phase 2 studies of PEGPH20 in patients with untreated mPDA and the treatment and management of musculoskeletal events with PEGPH20
Andrea J. Bullock, MD, MPH

Begin


Overall survival and immunologic responses in mPDAC on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)
J. Randolph Hecht, MD

Begin


Interim efficacy and safety results from the Phase 2 LAPACT trial and health-related quality of life
Philip A. Philip, MD, FRCP

Begin